|
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
RECRUITINGPhase 3Sponsored by Definium Therapeutics US, Inc.
Actively Recruiting
PhasePhase 3
SponsorDefinium Therapeutics US, Inc.
Started2024-12-11
Est. completion2026-05
Eligibility
Age18 Years – 74 Years
Healthy vol.Accepted
Locations36 sites
View on ClinicalTrials.gov →
NCT06741228
Summary
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Eligibility
Age: 18 Years – 74 YearsHealthy volunteers accepted
Inclusion Criteria: 1. Diagnosis of GAD per DSM-5 2. Male or female aged 18 to 74 3. HAM-A Total Score ≥20 Exclusion Criteria: 1. Certain psychiatric disorders (other than generalized anxiety disorder) 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine) 4. Any clinically significant unstable illness
Conditions2
AnxietyGeneralized Anxiety Disorder
Locations36 sites
Lighthouse Psychiatry
Gilbert, Arizona, 85234
Scottsdale Research Institute
Scottsdale, Arizona, 85022
Kadima Neuropsychiatry Institute
La Jolla, California, 92037
UCSF Department of Neurology
San Francisco, California, 94158
Psychedelic Science Institute
Santa Monica, California, 90404
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorDefinium Therapeutics US, Inc.
Started2024-12-11
Est. completion2026-05
Eligibility
Age18 Years – 74 Years
Healthy vol.Accepted
Locations36 sites
View on ClinicalTrials.gov →
NCT06741228